Table 1.
Study demography and clinical results
| Variable | Result (mean±SD), range, median or total (%) |
|---|---|
| CFT (um)* | |
| Pre IVI | 505±29 (range: 493-565; median: 507) |
| 24 months follow-up | 244±23 (range: 201-254; median: 241) |
| BCVA (log MAR)* | |
| Pre IVI | 0.82±0.13 (range: 0.8-1.3; median: 0.90) |
| 24 months follow-up | 0.38±0.06 (range: 0.2-0.4; median: 0.30) |
| IOP (mm Hg) | |
| Pre IVI | 15.1±2.2 (range: 12-19; median: 14.5) |
| 24 months follow-up | 16.9±3.1(range: 13-23; median: 16.5) |
| Number of injections (mean): | 1.2±0.6 |
| Eyes received one injection | 21 (72.4%) |
| Eyes required two injections | 8 (27.6%) |
| Follow-up time (months) | 24.75±0.9 |
| Pattern of VKH disease (patients): | |
| Complete | 3 |
| Incomplete | 5 |
| Probable | 8 |
| Pattern of Uveitis (eyes): | |
| Panuveitis | 24 (28.8%) |
| Posterior uveitis | 5 (17.2%) |
CFT (central foveal thickness), um (micrometer), BCVA (best-corrected visual acuity), IOP (intraocular pressure), IVI (intravitreal), VKH (Vogt-Koyanagi-Harada), SD (standard deviation), *A significant difference at P<0.05.